Erectile dysfunction and hypertension

International Journal of Impotence Research

Volumn 19, Issue 3, 2007, Pages 296-302

  Kloner, R ^a  

^a GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Alpha blockers; Cardiovascular risk factors; Erectile dysfunction; Hypertension; Phosphodiesterase inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMYL NITRATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; METOPROLOL; MORPHINE; NIFEDIPINE; NITRATE; ORGANIC NITRATE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT; VARDENAFIL;

ADJUVANT THERAPY; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHRONOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG LABELING; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; LOW DRUG DOSE; MONOTHERAPY; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; HUMANS; HYPERTENSION; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; RISK FACTORS;

EID: 34247850865     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901527     Document Type: Review

References (35)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
2. Burchardt M, Burchardt T, Baer L, Kiss AJ, Pawar RV, Shabsigh A et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 1188-1191.
3. Giuliano FA, Leriche A, Jaudinot EO, deGendre AS. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 2004; 64: 1196-1201.
4. Sun P, Swindle R. Are men with erectile dysfunction more likely to have hypertension than men without erectile dysfunction? A naturalistic national cohort study. J Urol 2005; 174: 244-248.
5. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus, and depression in men with erectile dysfunction. J Urol 2004; 171(6 Part 1): 2341-2345.
6. Wassertheil-Smoller S, Blaufox D, Oberman A, Davis BR, Swencionis C, Knerr MO et al. for the TAIM Research Group. Effect of antihypertensive on sexual function and quality of life: The TAIM Study. Ann Intern Med 1991; 114: 613-620.
7. Grimm Jr RH, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8-14.
8. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14: 27-31.
9. Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 1999; 18: 5-24.
10. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C-20C.
11. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83: 21C-28C.
12. Sildenafil Prescribing Information. Pfizer Inc.: New York, 2004.
13. Product monograph for Levitra (Vardenafil hydrochloride) Bayer Health Care: West Haven, CT and Glaxo SmithKline: Research Triangle Park, NC, 2003.
14. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl 2002; 4: H32-H47.
15. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92: 37M-46M.
16. Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576-582.
17. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83(Suppl 5A): 35C-44C.
18. Kloner RA, Brown M, Prisant LM, Collins M, for the Sildenafil Study Group. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens 2001; 14: 70-73.
19. Pickering TG, Mancia G, Glasser DB, Orazem J. Safety of Viagra (sildenafil citrate) in men with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive treatments. Am J Hypertens 2002; 15(Suppl 1): A55-A56.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
21. Kloner RA, Sadovsky R, Johnson EG, Mo D, Ahuja S. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impotence Res 2005; 17: 450-454.
22. Van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005; 2: 856-864.
23. Zusman RM, Prisant LM, Brown MJ, for the Sildenafil Study Group. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J Hypertens 2000; 18: 1865-1869.
24. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003; 92(Suppl): 47M-57M.
25. Padma-Nathan H, Porst H, Eardley I, Thibonnier M. Efficacy and safety of vardenafil, a selective phosphodieserase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy (abstract). Am J Hypertens 2002; 15: 48A.
26. Kloner RA, Mohan P, Segerson T, Thibonnier M, Norenberg C, Padma-Nathan H. Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of fine placebo-controlled trials. J Am Coll Cardiol 2003; 41(Suppl A): 276A-277A.
27. Pfizer Inc., New York, NY. [Based on a retrospective analysis of the intent-to-treat population from 25 double-blind, placebo-controlled, fixed and flexible-dose, clinical trials]. (data on file).
28. Cheitlin MD, Hutter Jr AM, Brindis RG, Ganz P, Kaul S, Russell Jr RO et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease: American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33: 273-282.
29. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42: 1855-1860.
30. Bayer Health Care, Glaxo Smith Kline, and Presented to US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee: Levitra tablets, 2003, (data on file).
31. Auerbach S, Gittelman M, Mazzu A, Sundaresan P, White W. Coadministered vardenafil (for erectile dysfunction) and tamsulosin do not induce hypotension in patients with benign prostatic hypertrophy. Am J Hypertension 2004; 17: 16A, Abstract OR35.
32. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on α-blocker interactions. Am J Cardiol 2005; 96: 42M-46M.
33. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR et al. Interaction between the phosphodiesterase 5 inhibitor tadalafil and 2 α-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172: 1935-1940.
34. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 313-321.
35. Kloner RA. Hypertension as a risk for erectile dysfunction: implications for sildenafil use. J Clin Hypertens 2000; 2: 33-36.